JP2016536369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536369A5 JP2016536369A5 JP2016552455A JP2016552455A JP2016536369A5 JP 2016536369 A5 JP2016536369 A5 JP 2016536369A5 JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016536369 A5 JP2016536369 A5 JP 2016536369A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- binding protein
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900246P | 2013-11-05 | 2013-11-05 | |
| US61/900,246 | 2013-11-05 | ||
| US201462016620P | 2014-06-24 | 2014-06-24 | |
| US62/016,620 | 2014-06-24 | ||
| PCT/US2014/063951 WO2015069668A1 (en) | 2013-11-05 | 2014-11-04 | Method of treating conditions of the eye with an anti-vegf darpin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106978A Division JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016536369A JP2016536369A (ja) | 2016-11-24 |
| JP2016536369A5 true JP2016536369A5 (https=) | 2018-02-22 |
Family
ID=51947485
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552455A Pending JP2016536369A (ja) | 2013-11-05 | 2014-11-04 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2020106978A Pending JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2022076645A Pending JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106978A Pending JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2022076645A Pending JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20150126458A1 (https=) |
| EP (2) | EP3065761B1 (https=) |
| JP (3) | JP2016536369A (https=) |
| KR (1) | KR20160070164A (https=) |
| CN (1) | CN105960247A (https=) |
| AU (2) | AU2014346921A1 (https=) |
| CA (1) | CA2927012A1 (https=) |
| DK (1) | DK3065761T3 (https=) |
| ES (1) | ES2773317T3 (https=) |
| HU (1) | HUE047910T2 (https=) |
| PL (1) | PL3065761T3 (https=) |
| PT (1) | PT3065761T (https=) |
| TW (1) | TWI729970B (https=) |
| WO (1) | WO2015069668A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| ES2753135T3 (es) | 2012-05-07 | 2020-04-07 | Allergan Inc | Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| JP7611173B2 (ja) * | 2019-06-04 | 2025-01-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｆａｐ結合タンパク質及びそれらの使用 |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| AU2021356298A1 (en) * | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| CA3197759A1 (en) | 2020-10-08 | 2022-04-14 | Notal Vision Ltd. | Oct guided therapy |
| CN114075290B (zh) * | 2022-01-20 | 2022-04-19 | 南京鼓楼医院 | Cd40靶向结合蛋白、其编码核酸以及用途 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| AU2007223855B2 (en) | 2006-03-06 | 2013-05-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| EP2111228B1 (en) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| BRPI0921469B1 (pt) * | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| AR081361A1 (es) * | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| ES2753135T3 (es) * | 2012-05-07 | 2020-04-07 | Allergan Inc | Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF |
-
2014
- 2014-11-04 PT PT148025448T patent/PT3065761T/pt unknown
- 2014-11-04 WO PCT/US2014/063951 patent/WO2015069668A1/en not_active Ceased
- 2014-11-04 EP EP14802544.8A patent/EP3065761B1/en active Active
- 2014-11-04 ES ES14802544T patent/ES2773317T3/es active Active
- 2014-11-04 EP EP19192065.1A patent/EP3628324A1/en not_active Withdrawn
- 2014-11-04 AU AU2014346921A patent/AU2014346921A1/en not_active Abandoned
- 2014-11-04 CN CN201480060463.5A patent/CN105960247A/zh active Pending
- 2014-11-04 KR KR1020167014741A patent/KR20160070164A/ko not_active Ceased
- 2014-11-04 US US14/532,397 patent/US20150126458A1/en not_active Abandoned
- 2014-11-04 PL PL14802544T patent/PL3065761T3/pl unknown
- 2014-11-04 JP JP2016552455A patent/JP2016536369A/ja active Pending
- 2014-11-04 CA CA2927012A patent/CA2927012A1/en not_active Abandoned
- 2014-11-04 HU HUE14802544A patent/HUE047910T2/hu unknown
- 2014-11-04 DK DK14802544.8T patent/DK3065761T3/da active
- 2014-11-05 TW TW103138456A patent/TWI729970B/zh not_active IP Right Cessation
-
2016
- 2016-08-05 US US15/230,244 patent/US20170157207A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,290 patent/US20210008158A1/en not_active Abandoned
- 2020-05-05 AU AU2020202968A patent/AU2020202968A1/en not_active Abandoned
- 2020-06-22 JP JP2020106978A patent/JP2020169191A/ja active Pending
-
2021
- 2021-10-13 US US17/500,315 patent/US20220175881A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076645A patent/JP2022107628A/ja active Pending